Dailypharm Live Search Close

AZ seeks reimb of its triple inhaled therapy for COPD

By Lee, Tak-Sun | translator Alice Kang

22.08.09 06:00:31

°¡³ª´Ù¶ó 0
AstraZeneca recently applied for reimbursement of its ¡®Breztri Aerosphere¡¯

Expected to compete with GSK¡¯s ¡®Trelegy Elipta,¡¯ which had been listed at a ¡®nice price¡¯

 ¡ãThe first single-inhaler triple therapy for COPD in Korea,

New triple drug inhaled therapies for COPD (Chronic Obstructive Pulmonary Disease) are working to receive insurance reimbursement in Korea. After GSK cut the first tape to reimbursement with its ¡®Trelegy Elipta¡¯ in June last year, AstraZeneca has also applied for the reimbursement of its ¡®Breztri Aerosphere,¡¯ which was approved in November last year.

According to industry sources on the 8th, AstraZeneca applied for reimbursement of its Breztri Aerosphere to the Health Insurance Review and Assessment Service.

Breztri Aerosphere is a single-inhaler, fixed-dose triple-combination of budesonide glycopyrrolate (undifferentiated), budesonide (undifferentiated), and formoterol fumarate (un

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)